By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
Its really difficult for these patients to lose weight, but it can provide a cure. According to Falardeau, research has shown that a 6% to 10% reduction of body weight can help patients achieve remission, with GLP-1 receptor agonists showing fantastic results in patients with non-vision-threatening IIH
The best course of action with any GLP-1 treatment is to continue your treatment plan for as long as possible to ensure you get maximum benefits
Users often experience a warm, sweaty, energized sensationsignaling elevated heat production and calorie burning
Regulatory classification is unclear
Plans start at $199 a month